An interventional study of tDCS and Aphasia therapy in Aphasia Following Cerebral Infarction, sponsored by University Hospital, Ghent. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Treatment
This study evaluates the neuromodulatory effect of combined tDCS and aphasia therapy in patients in the acute stage after stroke. Half of the participants will receive aphasia therapy and tDCS, the other half will receive aphasia therapy and sham-tDCS.
Aphasia is present in about one third of all stroke patients in the acute phase. The first few months after stroke, considerable spontaneous recovery is initiated, including neuronal plasticity and reorganization processes. Language recovery in aphasic stroke patients involves reorganization of brain functions. Longitudinal fMRI studies reveal that the right hemisphere shows increased activity at different times in the recovery process, but in the long-term is correlated with poorer performance. Left re-lateralization, if possible, seems to be the most effective in restoring language function. For a large subgroup of patients, aphasia therapy is not sufficient to resolve language deficits and not all patients are capable to endure intensive aphasia therapy. Therefore, non-invasive techniques (NIBS) such as transcranial direct current stimulation (tDCS) are currently explored as an add-on treatment to improve or accelerate therapy outcomes. tDCS is a painless and safe stimulation tool that modulates cortical excitability through weak polarizing currents (1 mA - 2 mA) between two electrodes. These weak currents are thought to induce a subthreshold shift of resting membrane potentials towards depolarization or hyperpolarization. The effects of stimulation depend on the polarity of the applied current relative to the axonal orientation. It has been found that tDCS not only triggers immediate aftereffects, but also long-lasting effects that persist beyond the stimulation time, even for up to 12 months. It was suggested that long-term potentiation (LTP) and long-term depression (LTD) might be responsible for these long-term effects, however the precise physiologic mechanisms of action are not yet fully understood.
Exclusion Criteria:
Device: tDCS · Behavioral: Aphasia therapy
Behavioral: Aphasia therapy · Device: Sham-tDCS
Device: Sham-tDCS
C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA
Based on linguistic tests, individualized aphasia therapy will be provided
tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
Change in naming performance
Naming performance will be assessed with the Boston Naming Test at baseline, immediately following therapy, and after 3 and 6 months
Time frame: baseline, 1 week, 3 months, 6 months
Change in Vital Parameters
Blood pressure and heart rate will be measured before and after each session of treatment
Time frame: baseline, 1 hour (each session)
Change in tolerability (Visual analogue scale)
A Visual analogue scale will assess tolerability before and immediately after each session
Time frame: baseline, 1 hour (each session)
Change in Spontaneous Speech
A Semi-standardized interview of the AAT will assess functional communication at baseline, immediately after therapy, and at 3 and 6 months
Time frame: baseline, 1 week, 3 months, 6 months
Change in ERPs
Evoked potentials will be measured at baseline, immediately after treatment and after 3 and 6 months
Time frame: baseline, 1 week, 3 months, 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Ghent